Evidence map›Paper›PMID 36467103›Full record

ArticleFrontiers in pharmacology2022

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity.

Xiaojie Chen, Long-Fei Mao, Siqi Tian, Xueli Tian, Xueqiong Meng, Mu-Kuo Wang, Weifeng Xu, Yue-Ming Li, Kangdong Liu, Zigang Dong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Xiaojie ChenSchool of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China.
Long-Fei MaoSchool of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China.
Siqi TianSchool of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China.
Xueli TianChina-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
Xueqiong MengSchool of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China.
Mu-Kuo WangSchool of Chemistry and Chemical Engineering, Henan Normal University, Henan Engineering Research Center of Chiral Hydroxyl Pharmaceutical, Xinxiang, China.
Weifeng XuDepartment of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Yue-Ming LiState Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, Tianjin, China.
Kangdong LiuChina-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
Zigang DongChina-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
China-US (Henan) Hormel Cancer Institute · CNHenan University of Science and Technology · CNNankai University · CNFirst Affiliated Hospital of Henan University of Science and Technology · CNHenan Cancer Hospital · CNHenan Normal University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous report showed that a variety of icotinib derivatives bearing different 1,2,3-triazole moieties, which could be readily prepared

Indexed as

1,2,3-triazoleEGFR-TK pathwayESCCicotinibNSCLC

Identifiers

PMID36467103
PMCPMC9709406
OpenAlexW4309312240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.